High materiality7/10
Vertex Pharmaceuticals resumed with an Overweight at Morgan Stanley
Why it may matterVerify against the original reporting
Positive but moderate upside given price level.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Morgan Stanley resumes VRTX with an Overweight; target 665 vs price 547.65, signaling ~21% upside.
- Morgan Stanley: VRTX Overweight; target 665; price 547.65.
Key facts
- 01
Target: $665
- 02
Posted price: $547.65
- 03
Analyst firm: Morgan Stanley
- 04
Analyst: Terence Flynn
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.